{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:07:03Z","timestamp":1767892023448,"version":"3.49.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/iae.0000000000000071","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T10:16:52Z","timestamp":1386325012000},"page":"951-957","source":"Crossref","is-referenced-by-count":53,"title":["NO CASES OF ENDOPHTHALMITIS AFTER 20,293 INTRAVITREAL INJECTIONS IN AN OPERATING ROOM SETTING"],"prefix":"10.1097","volume":"34","author":[{"given":"Troels","family":"Brynskov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben L.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ajo.2011.07.002","article-title":"Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics.","volume":"152","author":"Wykoff","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R2-16-20210130","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"De Jong-Hesse Y, et al.. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.","volume":"31","author":"van der Reis","year":"2011","journal-title":"Retina"},{"key":"R3-16-20210130","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.","volume":"31","author":"McCannel","year":"2011","journal-title":"Retina"},{"key":"R4-16-20210130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ajo.2010.08.039","article-title":"Survey of intravitreal injection techniques among retinal specialists in the United States.","volume":"151","author":"Green-Simms","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R6-16-20210130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","article-title":"Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment.","volume":"155","author":"Falk","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R7-16-20210130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R8-16-20210130","first-page":"1474","article-title":"Allen P, et al..","volume":"96","author":"Abell","year":"2012","journal-title":"Intravitreal injections: is there benefit for a theatre setting Br J Ophthalmol"},{"key":"R9-16-20210130","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","article-title":". A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration.","volume":"120","author":"Rasmussen","year":"2013","journal-title":"Ophthalmology"},{"key":"R10-16-20210130","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/bjophthalmol-2013-303222","article-title":". Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome.","volume":"97","author":"Mithal","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R11-16-20210130","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00417-013-2274-y","article-title":". Minimizing the endophthalmitis rate following intravitreal injections using 0.25 povidone-iodine irrigation and surgical mask.","volume":"251","author":"Shimada","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-16-20210130","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/IAE.0b013e31821067c4","article-title":". Endophthalmitis after intravitreal vascular corrected endothelial growth factor antagonists: a six-year experience at a university referral center.","volume":"31","author":"Moshfeghi","year":"2011","journal-title":"Retina"},{"key":"R13-16-20210130","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/IAE.0b013e3181884fd2","article-title":". Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.","volume":"28","author":"Fintak","year":"2008","journal-title":"Retina"},{"key":"R14-16-20210130","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ajo.2007.12.036","article-title":". Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.","volume":"145","author":"Pilli","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R15-16-20210130","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/IAE.0b013e318221594a","article-title":". Endophthalmitis after intravitreal injection: the importance of viridans streptococci.","volume":"31","author":"Chen","year":"2011","journal-title":"Retina"},{"key":"R16-16-20210130","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.ophtha.2012.02.014","article-title":". Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.","volume":"119","author":"Cheung","year":"2012","journal-title":"Ophthalmology"},{"key":"R17-16-20210130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/IAE.0b013e31819d2591","article-title":". Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.","volume":"29","author":"Diago","year":"2009","journal-title":"Retina"},{"key":"R18-16-20210130","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.ophtha.2011.02.034","article-title":". Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.","volume":"118","author":"Shah","year":"2011","journal-title":"Ophthalmology"},{"key":"R19-16-20210130","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/IAE.0b013e3181b32d27","article-title":". Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.","volume":"29","author":"Lima","year":"2009","journal-title":"Retina"},{"key":"R20-16-20210130","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/eye.2009.7","article-title":". Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection.","volume":"23","author":"Artunay","year":"2009","journal-title":"Eye (Lond)"},{"key":"R21-16-20210130","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":". Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R22-16-20210130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/IAE.0b013e3181ef463d","article-title":"Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.","volume":"31","author":"Inman","year":"2011","journal-title":"Retina"},{"key":"R23-16-20210130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R24-16-20210130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/IAE.0b013e3181633fee","article-title":". Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.","volume":"28","author":"Mason","year":"2008","journal-title":"Retina"},{"key":"R25-16-20210130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":". Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"R26-16-20210130","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":". Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R28-16-20210130","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":". HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"R29-16-20210130","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":". Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial.","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"R30-16-20210130","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":". Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"R31-16-20210130","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":". Ranibizumab for macular edema due to retinal vein occlusions.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R32-16-20210130","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":". Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"R33-16-20210130","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":". A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"R34-16-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":". Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R37-16-20210130","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":". Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"R38-16-20210130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3928\/15428877-20120119-01","article-title":"Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection.","volume":"43","author":"Lad","year":"2012","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R39-16-20210130","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":". Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R40-16-20210130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/archophthalmol.2009.304","article-title":". Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.","volume":"127","author":"Bhavsar","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R41-16-20210130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000329863","article-title":". Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.","volume":"226","author":"Inoue","year":"2011","journal-title":"Ophthalmologica"},{"key":"R42-16-20210130","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":". Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.","volume":"92","author":"Singerman","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R43-16-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":". Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).","volume":"246","author":"Wu","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R44-16-20210130","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archophthalmol.2011.227","article-title":". Bacterial dispersal associated with speech in the setting of intravitreous injections.","volume":"129","author":"Wen","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R45-16-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archopht.123.2.161","article-title":". Prospective randomized comparison of 2 different methods of 5 povidone-iodine applications for anterior segment intraocular surgery.","volume":"123","author":"Mino de Kaspar","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R46-16-20210130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/JCM.15.4.635-639.1982","article-title":"Increased bactericidal activity of dilute preparations of povidone-iodine solutions.","volume":"15","author":"Berkelman","year":"1982","journal-title":"J Clin Microbiol"},{"key":"R47-16-20210130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.2379","article-title":". Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection.","volume":"131","author":"Yin","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R48-16-20210130","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ophtha.2012.01.016","article-title":". Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.","volume":"119","author":"Milder","year":"2012","journal-title":"Ophthalmology"},{"key":"R49-16-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00006982-200602000-00012","article-title":". Vitreous penetration of topical moxifloxacin and gatifloxacin in humans.","volume":"26","author":"Costello","year":"2006","journal-title":"Retina"},{"key":"R50-16-20210130","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jcrs.2009.06.038","article-title":". Preoperative topical moxifloxacin 0.5 and povidone-iodine 5.0 versus povidone-iodine 5.0 alone to reduce bacterial colonization in the conjunctival sac.","volume":"35","author":"Halachimi-Eyal","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"R51-16-20210130","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ophtha.2009.02.024","article-title":"A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections.","volume":"116","author":"Moss","year":"2009","journal-title":"Ophthalmology"},{"key":"R52-16-20210130","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/eye.2012.199","article-title":". Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.","volume":"26","author":"Lyall","year":"2012","journal-title":"Eye (Lond)"},{"key":"R53-16-20210130","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ophtha.2010.02.030","article-title":"Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections.","volume":"117","author":"Moss","year":"2010","journal-title":"Ophthalmology"},{"key":"R54-16-20210130","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1097\/IAE.0b013e31820f4b4f","article-title":"Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate.","volume":"31","author":"Bhatt","year":"2011","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:01:44Z","timestamp":1620954104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201405000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000000071","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}